- Home
- INSM
INSM
Insmed Incorporated
as 11-26-2025 3:37pm EST
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | BRIDGEWATER |
| Market Cap: | 41.2B | IPO Year: | 2000 |
| Target Price: | $173.35 | AVG Volume (30 days): | 3.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 19 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $60.40 - $209.77 | Next Earning Date: | 10-30-2025 |
| Revenue: | $447,022,000 | Revenue Growth: | 30.34% |
| Revenue Growth (this year): | 40.09% | Revenue Growth (next year): | 129.64% |
Stock Insider Trading Activity of Insmed Incorporated (INSM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ANDERSON ELIZABETH M | INSM | Director | Nov 24 '25 | Sell | $204.58 | 5,000 | $1,022,900.00 | 58,729 | |
| LEE LEO | INSM | Director | Nov 17 '25 | Sell | $195.48 | 75,000 | $14,692,249.30 | 108,871 | |
| ANDERSON ELIZABETH M | INSM | Director | Nov 14 '25 | Sell | $195.87 | 10,000 | $1,958,700.00 | 58,729 | |
| Schaeffer Orlov S Nicole | INSM | Chief People Strategy Officer | Nov 12 '25 | Sell | $194.10 | 30,000 | $5,820,060.94 | 36,461 | |
| Flammer Martina M.D. | INSM | Chief Medical Officer | Nov 11 '25 | Sell | $189.78 | 31,226 | $5,922,794.88 | 86,024 | |
| Smith Michael Alexander | INSM | Chief Legal Officer | Nov 3 '25 | Sell | $184.42 | 27,130 | $4,985,910.59 | 54,902 | |
| Schaeffer Orlov S Nicole | INSM | Chief People Strategy Officer | Sep 12 '25 | Sell | $146.08 | 76,520 | $11,129,927.45 | 36,461 | |
| SHAROKY MELVIN MD | INSM | Director | Sep 12 '25 | Sell | $145.39 | 10,000 | $1,453,900.00 | 262,675 | |
| Flammer Martina M.D. | INSM | Chief Medical Officer | Sep 2 '25 | Sell | $143.65 | 186,648 | $26,941,272.29 | 86,024 | |
| Smith Michael Alexander | INSM | Chief Legal Officer | Sep 2 '25 | Sell | $143.60 | 24,272 | $3,492,377.99 | 54,902 |
Latest Insmed Incorporated News
INSM Breaking Stock News: Dive into INSM Ticker-Specific Updates for Smart Investing
Simply Wall St.
a day ago
Is EU Approval of First NCFB Therapy Reframing Insmed’s (INSM) Investment Outlook?
Simply Wall St.
2 days ago
What Catalysts Are Shaping the New Narrative for Insmed?
Insider Monkey
2 days ago
Insmed (INSM) Rose Following Drug Approval
24/7 Wall St.
2 days ago
This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks He’s Buying Now.
Zacks
8 days ago
Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri
Argus Research
8 days ago
Daily – Vickers Top Buyers & Sellers for 11/19/2025
MT Newswires
9 days ago
Insmed Says European Commission Approves Brinsupri for Treatment of Non-Cystic Fibrosis Bronchiectasis
PR Newswire
9 days ago
European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
Compare INSM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INSM Insmed Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.